PROFILE OF PROCALCITONIN LEVELS IN SEVERE–CRITICAL COVID-19 PATIENTS

Asyikun Nasyid Room, Hisbullah Amin, Faisal Muchtar

Abstract


The diagnostic and therapeutic modalities of COVID-19 are still being researched and developed. One of the diagnostic modalities in the treatment of COVID-19, especially in patients with severe and critical symptoms, is procalcitonin. Although procalcitonin is more commonly associated with bacterial infections, several studies have shown association between the severity of COVID-19 patients and procalcitonin levels, and serial measurement of procalcitonin levels may be useful in predicting prognosis. This report presents three cases of severe-critically ill COVID-19. All three patients were tested for procalcitonin serially. Survivors (patient I and II) showed relatively low procalcitonin levels. These patients were clinically responsive to conventional oxygen therapy modalities. Serial chest X-rays in both patients also did not show the progression of pneumonia. In non-survivor (patient III) procalcitonin level have shown high value before ICU treatment, and during ICU care showed an increasing trend. The increase was in line with the progression of pneumonia on chest X-ray, and the patient is also clinically unresponsive to oxygen therapy, requiring invasive mechanical ventilation. Procalcitonin examination is one of the modalities that can be used in predicting the prognosis and disease course of severe-critical COVID-19 patients. COVID-19 patients with low procalcitonin levels are associated with a better prognosis than patients with high procalcitonin levels.


Keywords


COVID-19, severe-critical, procalcitonin

Full Text:

PDF

References


https://covid19.go.id/peta-sebaran-covid19; diakses 24 Mei 2021.

Manasia A, Narimasu J. Biomarkers in Decision Making. In Oropello JM, Kvetan V, Pastores SM (ed.) Critical Care, 1st ed, New York : McGraw-Hill, 2016: p.78

Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clinica Chimica Acta 505. 2020; 190–191.

Hu R, Han C, Pei S, et al. Procalcitonin levels in COVID-19 patients. International Journal of Antimicrobial Agents 56. 2020;106051.

Savio RD. Procalcitonin (in COVID-19): The Incessant Quest. Indian J Crit Care Med. 2021;25(1):1–2.

Gregoriano C, Koch D, Haubitz S, et al. Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis. Swiss Med Wkly, 2020; 150:w20316. doi: 10.4414/smw.2020.20316

Huang I, Pranata R, Lim MA. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020; Vol. 14: 1–14, DOI: 10.1177/1753466620937175

Ahmed S, Jafri L, Hoodbhoy Z, et al. Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review. Indian J Crit Care Med. 2021;25(1):77–84.

Liu Z, Li J, Wang S, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J Med Sci. 2020; 17(16): 2468-2476. doi: 10.7150/ijms.48396

Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011; 52 (suppl 4):S346–50.

Mahmudpoura M, Roozbehb J, Keshavarza M, et al. COVID-19 cytokine storm: The anger of inflammation. Cytokine 133. 2020; 155151.

Mahallawi WH, Khabour OF, Zhang Q, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104. 2018; 8–13.

Huang C, Wang Y, Li Xingwang, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395. 10.1016/S0140-6736(20)30183-5.

Chen T, Wu D, Chen H, et.al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019:retrospective study, BMJ 368, 2020.

Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison withother inflammatory syndromes. Lancet Respir Med, 2020;8: 1233–44

Wiiliams P, McWilliams C, Soomro K, et al. The dynamics of procalcitonin in COVID-19 patients admitted to Intensive care unit - a multi-centre cohort study in the South West of England, UK. Journal of Infection 82. 2021; e24–e26.

Williams EJ, Mair L, de Silva TI, et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. Journal of Hospital Infection 110. 2021; 103e107.

Vanhomwegen C, Veliziotis I, Malinverni S, et al. Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit [published online ahead of print, 2021 Jan 16]. Ir J Med Sci. 2021;1-4. doi:10.1007/s11845-020-02485-z

Garrido P, Cueto P, Rovira C, et al. Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2 [published online ahead of print, 2020 Nov 8]. Am J Emerg Med. 2020; S0735-6757(20)31020-2. doi:10.1016/j.ajem.2020.11.011

Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med. 2003;29:579–583.




DOI: https://doi.org/10.26618/aimj.v4i2.5960

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.